Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Topica Pharmaceuticals (Palo Alto, CA) a clinical-stage pharmaceutical company focused on treatments for onychomycosis, closed a $27M Series B financing. Participants include Third Rock Ventures, Prospect Venture Partners and Yasuda Enterprise Development Corporation.

Lytix Biopharma (Norway) pre-clinical developer of lytic peptide drugs for the treatment of resistant bacterial, fungal infections and tumor progression, closed a $10.4M Series D financing. Participants in financings have included Picasso Kapital, Såkorninvest Nord, Norinnova, Sparebanken Nord-Norge Invest, Serepta, Rekdal, Svendsen, Norinnova Invest and Taj Holding.

SpePharm (Netherlands) commercial-stage marketer of anti-fungal and mucositis drugs to the EU market, closed a $20.3M Series C financing. Participants included TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare.

Myconostica (Manchester, England) early-stage company focused on the treatment of Pneumocystis and Aspergillus infections, closed a $9.7M Series A financing. Participants include Nexus Medical Partners, Innoven Partenaires, Medicis Ventures and Amphion Innovations.


to top of page...